PMID- 32528890
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210322
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 10
DP  - 2020
TI  - Effectiveness and Safety of Pyrotinib, and Association of Biomarker With 
      Progression-Free Survival in Patients With HER2-Positive Metastatic Breast 
      Cancer: A Real-World, Multicentre Analysis.
PG  - 811
LID - 10.3389/fonc.2020.00811 [doi]
LID - 811
AB  - Background: Pyrotinib, an irreversible pan-ERBB inhibitor, has shown promising 
      antitumour activity, and acceptable tolerability. This research was conducted to 
      evaluate the actual use and effectiveness of pyrotinib in China, therefore, 
      contributed to solve the problem of real-world data scarcity. Methods: In this 
      retrospective study, 168 patients who received pyrotinib treatment for 
      HER2-positive metastatic breast cancer (MBC) in Hunan Province from June 2018 to 
      August 2019 were included. Progression-free survival (PFS), tumor mutation burden 
      (TMB), and drug-related adverse events (AEs) after pyrotinib administration were 
      analyzed. Results: The median PFS (mPFS) time in the 168 participants was 8.07 
      months. The mPFS times in patients with pyrotinib in second-line therapy (n = 65) 
      and third-or-higher-line therapy (n = 94) were 8.10 months and 7.60 months, 
      respectively. Patients with brain metastases achieved 8.80 months mPFS time. In 
      patients with pyrotinib in third-or-higher-line therapy, patients who had 
      previously used lapatinib still got efficacy but showed a shorter mPFS time (6.43 
      months) than patients who had not (8.37 months). TMB was measured in 28 patients, 
      K-M curve (P = 0.0024) and Multivariate Cox analysis (P = 0.0176) showed a 
      significant negative association between TMB and PFS. Diarrhea occurred in 98.2% 
      of participants (in any grade) and 19.6% in grade 3-4 AEs. Conclusion: Pyrotinib 
      is highly beneficial to second-or-higher-line patients or HER2-positive MBC 
      patients with brain metastases. Pyrotinib seems to be a feasible strategy both in 
      combination of chemotherapeutic drugs or as a replacement of lapatinib if 
      diseases progressed. TMB could be a potential predictor for evaluating 
      pyrotinib's effectiveness in HER2-positive MBC.
CI  - Copyright (c) 2020 Chen, Ouyang, Anwar, Xie, Wang, Fan, Qian, Chen, Zhou, Guo, Gu, 
      Ding, Yang, Liu, Deng, Xiao, Li, Wang, Zeng, Hu, Zhou, Qiu, Wang, Weng, Liu, Li, 
      Tang, Wang, Zhang, Dai, Tang, Wu, Xiao, Li, Liu, Li, Yi and Ouyang.
FAU - Chen, Qitong
AU  - Chen Q
AD  - Department of General Surgery, The Second Xiangya Hospital, Central South 
      University, Changsha, China.
FAU - Ouyang, Dengjie
AU  - Ouyang D
AD  - Department of General Surgery, The Second Xiangya Hospital, Central South 
      University, Changsha, China.
AD  - Department of General Surgery, Xiangya Hospital Central South University, 
      Changsha, China.
FAU - Anwar, Munawar
AU  - Anwar M
AD  - Department of General Surgery, The Second Xiangya Hospital, Central South 
      University, Changsha, China.
FAU - Xie, Ning
AU  - Xie N
AD  - Department of Breast Internal Medicine, The Affiliated Cancer Hospital of Xiangya 
      School of Medicine, Central South University, Changsha, China.
FAU - Wang, Shouman
AU  - Wang S
AD  - Department of Breast Surgery, Xiangya Hospital, Central South University, 
      Changsha, China.
FAU - Fan, Peizhi
AU  - Fan P
AD  - Department of Breast and Thyroid Surgery, Hunan Provincial People's Hospital, 
      Changsha, China.
FAU - Qian, Liyuan
AU  - Qian L
AD  - Department of Breast and Thyroid Surgery, Central South University Third Xiangya 
      Hospital, Changsha, China.
FAU - Chen, Gannong
AU  - Chen G
AD  - Department of General Surgery, The Second Xiangya Hospital, Central South 
      University, Changsha, China.
FAU - Zhou, Enxiang
AU  - Zhou E
AD  - Department of General Surgery, The Second Xiangya Hospital, Central South 
      University, Changsha, China.
FAU - Guo, Lei
AU  - Guo L
AD  - Department of Breast Surgery, Xiangya Hospital, Central South University, 
      Changsha, China.
FAU - Gu, Xiaowen
AU  - Gu X
AD  - Department of Breast and Thyroid Surgery, Hunan Provincial People's Hospital, 
      Changsha, China.
FAU - Ding, Boni
AU  - Ding B
AD  - Department of Breast and Thyroid Surgery, Central South University Third Xiangya 
      Hospital, Changsha, China.
FAU - Yang, Xiaohong
AU  - Yang X
AD  - Department of Oncology, The Affiliated Cancer Hospital of Xiangya School of 
      Medicine, Cental South University, Changsha, China.
FAU - Liu, Liping
AU  - Liu L
AD  - Department of Oncology, The Affiliated Cancer Hospital of Xiangya School of 
      Medicine, Cental South University, Changsha, China.
FAU - Deng, Chao
AU  - Deng C
AD  - Department of Oncology, The Second Xiangya Hospital, Central South University, 
      Changsha, China.
FAU - Xiao, Zhi
AU  - Xiao Z
AD  - Department of Breast Internal Medicine, The Affiliated Cancer Hospital of Xiangya 
      School of Medicine, Central South University, Changsha, China.
FAU - Li, Jing
AU  - Li J
AD  - Department of Breast Medical Oncology, The Affiliated Cancer Hospital of Xiangya 
      School of Medicine, Cental South University, Changsha, China.
FAU - Wang, Yunqi
AU  - Wang Y
AD  - Department of Traditional Chinese Medicine, The Affiliated Cancer Hospital of 
      Xiangya School of Medicine, Cental South University, Changsha, China.
FAU - Zeng, Shan
AU  - Zeng S
AD  - Department of Internal Medicine - Oncology, Xiangya Hospital Central South 
      University, Changsha, China.
FAU - Hu, Jinhui
AU  - Hu J
AD  - Department of Breast Surgery, The First Hospital Hunan University of Chinese 
      Medicine, Changsha, China.
FAU - Zhou, Wei
AU  - Zhou W
AD  - Department of Breast and Thyroid Surgery, The Affiliated ZhuZhou Hospital of 
      Xiangya School of Medicine Central South University, Zhuzhou, China.
FAU - Qiu, Bo
AU  - Qiu B
AD  - Department of Oncology, The Affiliated ZhuZhou Hospital of Xiangya School of 
      Medicine Central South University, Zhuzhou, China.
FAU - Wang, Zhongming
AU  - Wang Z
AD  - Department of Breast Surgery, The Third People's Hospital of Yongzhou, Yongzhou, 
      China.
FAU - Weng, Jie
AU  - Weng J
AD  - Department of Oncology, The First People's Hospital of Yueyang, Yueyang, China.
FAU - Liu, Mingwen
AU  - Liu M
AD  - Department of Breast and Thyroid Surgery, The First People's Hospital of Xiangtan 
      City, Xiangtan, China.
FAU - Li, Yi
AU  - Li Y
AD  - Department of Oncology, The Third People's Hospital of Changde, Changde, China.
FAU - Tang, Tiegang
AU  - Tang T
AD  - Department of Oncology, Xiangtan Central Hospital, Xiangtan, China.
FAU - Wang, Jianguo
AU  - Wang J
AD  - Department of General Surgery, Xiangtan Central Hospital, Xiangtan, China.
FAU - Zhang, Hui
AU  - Zhang H
AD  - Department of Oncology, Central Hospital of Shaoyang, Shaoyang, China.
FAU - Dai, Bin
AU  - Dai B
AD  - Department of Breast and Thyroid Surgery, Central Hospital of Shaoyang, Shaoyang, 
      China.
FAU - Tang, Wuping
AU  - Tang W
AD  - Department of Breast Surgery, Shaoyang Hospital of Traditional Chinese Medicine, 
      Shaoyang, China.
FAU - Wu, Tao
AU  - Wu T
AD  - Department of Oncology, The First People's Hospital of Changde, Changde, China.
FAU - Xiao, Maoliang
AU  - Xiao M
AD  - Department of Oncology, The Third Hospital of Hunan University of Chinese 
      Medicine, Zhuzhou, China.
FAU - Li, Xiantao
AU  - Li X
AD  - Department of Oncology, The Central Hospital of Yiyang, Yiyang, China.
FAU - Liu, Hailong
AU  - Liu H
AD  - Department of Internal Medicine - Oncology, The First People's Hospital of 
      Chenzhou, Chenzhou, China.
FAU - Li, Lai
AU  - Li L
AD  - Department of Breast and Thyroid Surgery, The People's Hospital of Xiangtan 
      County, Xiangtan, China.
FAU - Yi, Wenjun
AU  - Yi W
AD  - Department of General Surgery, The Second Xiangya Hospital, Central South 
      University, Changsha, China.
FAU - Ouyang, Quchang
AU  - Ouyang Q
AD  - Department of Breast Internal Medicine, The Affiliated Cancer Hospital of Xiangya 
      School of Medicine, Central South University, Changsha, China.
LA  - eng
PT  - Journal Article
DEP - 20200525
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
EIN - Front Oncol. 2021 Mar 05;11:661128. PMID: 33747972
PMC - PMC7263174
OTO - NOTNLM
OT  - HER2
OT  - breast cancer
OT  - metastases
OT  - pyrotinib
OT  - tumor mutation burden
EDAT- 2020/06/13 06:00
MHDA- 2020/06/13 06:01
PMCR- 2020/01/01
CRDT- 2020/06/13 06:00
PHST- 2020/01/23 00:00 [received]
PHST- 2020/04/24 00:00 [accepted]
PHST- 2020/06/13 06:00 [entrez]
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2020/06/13 06:01 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2020.00811 [doi]
PST - epublish
SO  - Front Oncol. 2020 May 25;10:811. doi: 10.3389/fonc.2020.00811. eCollection 2020.